Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ilacirnon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 known ✓ | P41597 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.84 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilacirnon SCHEMBL31378455 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL125684 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL29395065 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL30231013 | 1.00 | CCR2 (1.00) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| Ilacirnon SCHEMBL125683 | 0.99 | CCR2 (0.98) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| SCHEMBL1188630 | 0.92 | CYP3A4 (0.84) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| SCHEMBL128785 | 0.92 | CYP2C9 (1.00) | CCR2CYP3A4CYP2C9JAK1 | |
| SCHEMBL127931 | 0.90 | CCR2 (0.81) | CCR2CYP3A4CYP2C9BRAFTNNI3K | |
| SCHEMBL12594931 | 0.90 | CCR2 (0.81) | CCR2CYP3A4CYP2C9JAK1BRAF | |
| SCHEMBL130501 | 0.89 | CCR2 (0.81) | CCR2CYP3A4CYP2C9JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2175859-B1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESULFONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | CHEMOCENTRYX INC (US) | 2012-03-07 | — | — | EP | claimed |
| EP-3463350-B1 | PYRROLO-PYRIDINES AND PYRROLO-PYRIMIDINES FOR USE IN TREATING LIVER FIBROSIS | CHEMOCENTRYX INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4134080-A1 | CCR2 INHIBITORS FOR USE IN TREATING RENAL DISEASES | ChemoCentryx, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11382915-B2 | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11357760-B2 | Method of treating liver fibrosis | CHEMOCENTRYX, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11324736-B2 | Method of Treating Focal Segmental Glomerulosclerosis | CHEMOCENTRYX, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-7884110-B2 | 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide sodium salt; for chemokine-mediated conditions or diseases including certain inflammatory and immunoregulatory disorders; restenosis, multiple sclerosis, arthritis | CHEMOCENTRYX, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884110-B2 | 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide sodium salt; for chemokine-mediated conditions or diseases including certain inflammatory and immunoregulatory disorders; restenosis, multiple sclerosis, arthritis | CHEMOCENTRYX, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884110-B2 | 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide sodium salt; for chemokine-mediated conditions or diseases including certain inflammatory and immunoregulatory disorders; restenosis, multiple sclerosis, arthritis | CHEMOCENTRYX, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2175859-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESULFONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | ChemoCentryx Inc (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2009-09-17 | — | — | US | disclosed |
| WO-2009009740-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009009740-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CCR2 1/4885CYP3A4 1934/4885CYP2C9 192/4885 |
| US-11382915-B2 | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists | REN, CCR2, AGTR2 | CCR2 2/4885CYP3A4 4759/4885CYP2C9 4681/4885 |
| US-11324736-B2 | Method of Treating Focal Segmental Glomerulosclerosis | SLC5A1, PTGFR, HPGDS | CCR2 610/4885CYP3A4 3325/4885CYP2C9 2646/4885 |
| US-20090233946-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CCR2 1/4885CYP3A4 1134/4885CYP2C9 1281/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | CCR2 1/4885CYP3A4 3935/4885CYP2C9 3501/4885 |
| US-11357760-B2 | Method of treating liver fibrosis | CCR2, CMKLR2, CCL2 | CCR2 1/4885CYP3A4 1173/4885CYP2C9 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.